$CLDX
Celldex Therapeutics, Inc. Stock $cldx

$cldx Overview Financials Valuation SEC Filings Company Website

2012 Q1 Form 10-K Financial Statement

#000104746912002276 Filed on March 08, 2012

Income Statement

Concept	2012 Q1	2011	2010 Q4
Revenue	$2.433M	$9.265M	$37.72M
YoY Change	-3.3%	-80.2%	697.46%
Cost Of Revenue	$2.340M	$9.120M	$6.800M
YoY Change	-6.4%	-24.5%	149.08%
Gross Profit	$90.00K	$150.0K	$30.92M
YoY Change	800.0%	-99.57%	1438.31%
Gross Profit Margin	3.7%	1.62%	81.97%
Selling, General & Admin	$2.320M	$9.190M	$2.530M
YoY Change	-2.93%	-11.46%	-60.59%
% of Gross Profit	2577.78%	6126.67%	8.18%
Research & Development	$10.77M	$32.44M	$6.740M
YoY Change	57.14%	17.32%	-16.89%
% of Gross Profit	11965.56%	21626.0%	21.8%
Depreciation & Amortization	$544.0K	$2.248M	$1.010M
YoY Change	-3.2%	-17.29%	-21.09%
% of Gross Profit	604.44%	1498.67%	3.27%
Operating Expenses	$10.77M	$32.44M	$9.800M
YoY Change	57.14%	17.32%	-35.48%
Operating Profit	-$13.29M	-$43.40M	$21.12M
YoY Change	37.59%	572.33%	-260.24%
Interest Expense	$433.0K	$1.796M	$1.540M
YoY Change	-10.72%	34.33%	-631.03%
% of Operating Profit			7.29%
Other Income/Expense, Net
YoY Change
Pretax Income	-$13.52M	-$44.80M	$22.66M
YoY Change	34.39%	1668.61%	-268.23%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$13.52M	-$44.80M	$22.66M
YoY Change	34.39%	1670.75%	-275.12%
Net Earnings / Revenue	-555.69%	-483.54%	60.07%
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.048M	-$17.03M	$10.39M
COMMON SHARES
Basic Shares Outstanding	57.16M shares
Diluted Shares Outstanding		39.50M shares

Balance Sheet

Concept	2012 Q1	2011	2010 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$92.10M	$53.30M	$61.10M
YoY Change	107.9%	-12.77%	-25.94%
Cash & Equivalents	$22.76M	$11.90M	$21.29M
Short-Term Investments	$69.40M	$41.40M	$39.80M
Other Short-Term Assets	$2.000M	$1.200M	$1.500M
YoY Change	17.65%	-20.0%	50.0%
Inventory
Prepaid Expenses
Receivables	$100.0K	$200.0K	$300.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$94.24M	$54.70M	$62.95M
YoY Change	103.97%	-13.04%	-25.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.400M	$9.100M	$10.83M
YoY Change	-20.0%	-15.74%	-5.81%
Goodwill			$8.965M
YoY Change
Intangibles			$26.84M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$500.0K	$300.0K	$363.0K
YoY Change	25.0%	-25.0%	-93.95%
Total Long-Term Assets	$42.50M	$43.30M	$47.00M
YoY Change	-8.0%	-7.87%	-16.67%
TOTAL ASSETS
Total Short-Term Assets	$94.24M	$54.70M	$62.95M
Total Long-Term Assets	$42.50M	$43.30M	$47.00M
Total Assets	$136.7M	$98.00M	$109.9M
YoY Change	47.99%	-10.83%	-21.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$500.0K	$900.0K	$931.0K
YoY Change	-28.57%	0.0%	-33.5%
Accrued Expenses	$6.400M	$7.000M	$4.936M
YoY Change	52.38%	42.86%	-11.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.300M	$6.100M	$13.50M
YoY Change	60.61%	-54.81%
Total Short-Term Liabilities	$12.50M	$14.30M	$20.21M
YoY Change	40.45%	-29.21%	40.33%
LONG-TERM LIABILITIES
Long-Term Debt	$9.900M	$9.000M	$8.900M
YoY Change	-15.38%	1.12%	-23.93%
Other Long-Term Liabilities	$6.400M	$6.000M	$5.591M
YoY Change	6.67%	7.14%	-86.2%
Total Long-Term Liabilities	$16.30M	$15.00M	$5.591M
YoY Change	-7.91%	3.45%	-89.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.50M	$14.30M	$20.21M
Total Long-Term Liabilities	$16.30M	$15.00M	$5.591M
Total Liabilities	$28.85M	$29.30M	$34.69M
YoY Change	8.47%	-15.56%	-47.92%
SHAREHOLDERS EQUITY
Retained Earnings			-$160.2M
YoY Change
Common Stock			$232.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$107.9M	$68.70M	$75.26M
YoY Change
Total Liabilities & Shareholders Equity	$136.7M	$98.00M	$109.9M
YoY Change	47.99%	-10.83%	-21.69%

Cashflow Statement

Concept	2012 Q1	2011	2010 Q4
OPERATING ACTIVITIES
Net Income	-$13.52M	-$44.80M	$22.66M
YoY Change	34.39%	1670.75%	-275.12%
Depreciation, Depletion And Amortization	$544.0K	$2.248M	$1.010M
YoY Change	-3.2%	-17.29%	-21.09%
Cash From Operating Activities	-$13.55M	-$35.66M	-$6.010M
YoY Change	52.93%	17.42%	-44.56%
INVESTING ACTIVITIES
Capital Expenditures	$42.00K	$509.0K	-$440.0K
YoY Change	-79.21%	-75.76%	388.89%
Acquisitions
YoY Change
Other Investing Activities	-$27.47M	-$1.650M	$7.950M
YoY Change	-602.19%	-88.26%	-82.24%
Cash From Investing Activities	-$27.51M	-$2.160M	$7.510M
YoY Change	-622.01%	-86.63%	-83.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$51.93M	$36.02M
YoY Change		3452.56%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	51.91M	28.43M	9.960M
YoY Change	-787.55%	162.75%	-451.94%
NET CHANGE
Cash From Operating Activities	-13.55M	-35.66M	-6.010M
Cash From Investing Activities	-27.51M	-2.160M	7.510M
Cash From Financing Activities	51.91M	28.43M	9.960M
Net Change In Cash	10.85M	-9.390M	11.46M
YoY Change	-197.4%	-73.7%	-63.04%
FREE CASH FLOW
Cash From Operating Activities	-$13.55M	-$35.66M	-$6.010M
Capital Expenditures	$42.00K	$509.0K	-$440.0K
Free Cash Flow	-$13.59M	-$36.17M	-$5.570M
YoY Change	49.99%	11.39%	-48.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2010	cldx	Revenue From Product Development And Licensing Agreements RevenueFromProductDevelopmentAndLicensingAgreements	40187000	USD
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31868000	shares
CY2009	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-12000	USD
CY2009	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-36525000	USD
CY2009	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19823000	shares
CY2010	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3143000	USD
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44210636	shares
CY2010Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	232679000	USD
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	297000000	shares
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011	dei	Entity Registrant Name EntityRegistrantName	Celldex Therapeutics, Inc.
CY2011	dei	Entity Central Index Key EntityCentralIndexKey	0000744218
CY2011	dei	Amendment Flag AmendmentFlag	false
CY2011	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2011	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2011	dei	Document Type DocumentType	10-K
CY2011	dei	Document Period End Date DocumentPeriodEndDate	2011-12-31
CY2009	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	949000	USD
CY2010	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	14000	USD
CY2010	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	4000	USD
CY2009	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-24000	USD
CY2010	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	38000	USD
CY2009	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	556000	USD
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	2802000	USD
CY2009	us-gaap	Share Based Compensation ShareBasedCompensation	3058000	USD
CY2010	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	728000	USD
CY2009	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	181000	USD
CY2010	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-220000	USD
CY2009	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1283000	USD
CY2010	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	546000	USD
CY2009	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-743000	USD
CY2010Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	75255000	USD
CY2010Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-160207000	USD
CY2010Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2751000	USD
CY2010Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32055382	shares
CY2010Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32055382	shares
CY2010Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	297000000	shares
CY2010Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2010Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2010Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2010Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44210636	shares
CY2011	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2011	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2011	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2011Q2	dei	Entity Public Float EntityPublicFloat	156100000	USD
CY2012Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57160636	shares
CY2011	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2011
CY2011	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2009	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.84
CY2009	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-529000	USD
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2533000	USD
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31868000	shares
CY2010	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2533000	USD
CY2010	us-gaap	Interest Expense InterestExpense	1337000	USD
CY2010	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5259000	USD
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	-6455000	USD
CY2010	us-gaap	Costs And Expenses CostsAndExpenses	53248000	USD
CY2010	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10428000	USD
CY2010	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	50000	USD
CY2010	cldx	Revenue From Contracts And Grants RevenueFromContractsAndGrants	220000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44799000	USD
CY2009	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36585000	USD
CY2010	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-5592000	USD
CY2009	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-722000	USD
CY2010	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1193000	USD
CY2009	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2463000	USD
CY2011	us-gaap	Revenues Revenues	9265000	USD
CY2009	cldx	Revenue From Product Development And Licensing Agreements RevenueFromProductDevelopmentAndLicensingAgreements	5662000	USD
CY2010Q4	us-gaap	Common Stock Value CommonStockValue	32000	USD
CY2010Q4	us-gaap	Liabilities Liabilities	34688000	USD
CY2010Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5591000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	68722000	USD
CY2011Q4	us-gaap	Liabilities Liabilities	29272000	USD
CY2011Q4	us-gaap	Assets Assets	97994000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	54684000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21287000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11899000	USD
CY2010Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2010Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	109943000	USD
CY2009	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37054000	USD
CY2009	us-gaap	Interest Expense InterestExpense	452000	USD
CY2009	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	248000	USD
CY2009	us-gaap	Operating Income Loss OperatingIncomeLoss	-36850000	USD
CY2009	us-gaap	Costs And Expenses CostsAndExpenses	52030000	USD
CY2009	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17119000	USD
CY2009	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	604000	USD
CY2009	us-gaap	Royalty Expense RoyaltyExpense	8397000	USD
CY2009	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26169000	USD
CY2009	us-gaap	Revenues Revenues	15180000	USD
CY2009	us-gaap	Royalty Revenue RoyaltyRevenue	7716000	USD
CY2009	cldx	Revenue From Contracts And Grants RevenueFromContractsAndGrants	1802000	USD
CY2010	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2328000	USD
CY2010	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2000	USD
CY2010	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-39382000	USD
CY2009	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2038000	USD
CY2010	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1865000	USD
CY2009	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2699000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-35658000	USD
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-30372000	USD
CY2009	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-29869000	USD
CY2009	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	51654000	USD
CY2010	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	42383000	USD
CY2009	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2674000	USD
CY2010	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	56522000	USD
CY2009	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9559000	USD
CY2008Q4	us-gaap	Stockholders Equity StockholdersEquity	18134000	USD
CY2009	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	917000	USD
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2100000	USD
CY2009	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	528000	USD
CY2010	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	77000	USD
CY2009	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	850000	USD
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-16162000	USD
CY2009	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	45091000	USD
CY2010	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1014000	USD
CY2009	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	668000	USD
CY2010Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	8889000	USD
CY2010Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20208000	USD
CY2010Q4	us-gaap	Convertible Subordinated Debt Current ConvertibleSubordinatedDebtCurrent	12412000	USD
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2010Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	1111000	USD
CY2010Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	818000	USD
CY2010Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4936000	USD
CY2010Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	931000	USD
CY2010Q4	us-gaap	Assets Assets	109943000	USD
CY2010Q4	us-gaap	Goodwill Goodwill	8965000	USD
CY2010Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	363000	USD
CY2010Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26836000	USD
CY2010Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10832000	USD
CY2010Q4	us-gaap	Assets Current AssetsCurrent	62947000	USD
CY2010Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1525000	USD
CY2010Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	324000	USD
CY2010Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	39811000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97994000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57002000	USD
CY2008Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44257000	USD
CY2009	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	250000	USD
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2718000	USD
CY2009	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2583000	USD
CY2009	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	88243000	USD
CY2009	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3058000	USD
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	73767000	USD
CY2011	us-gaap	Basis Of Accounting BasisOfAccounting	<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="FONT-FAMILY: times"><font size="2"><b>(1) NATURE OF BUSINESS AND OVERVIEW </b></font></p> <p style="FONT-FAMILY: times"><font size="2">        Celldex Therapeutics, Inc. (the "Company" or "Celldex") is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's lead drug candidates include rindopepimut (CDX-110), an immunotherapeutic vaccine in a pivotal Phase 3 study for the treatment of glioblastoma, CDX-011, an antibody-drug conjugate in a randomized Phase 2b study for the treatment of advanced breast cancer and CDX-1127, a therapeutic human antibody in a Phase 1 study for cancer indications. The Company has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology™ program, CDX-301, an immune cell mobilizing agent, and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. The Company's collaboration with GlaxoSmithKline (Glaxo) resulted in the commercialization of Rotarix, an oral human rotavirus vaccine. </font></p> <p style="FONT-FAMILY: times"><font size="2">        At December 31, 2011, the Company had cash, cash equivalents and marketable securities of $53.3 million; working capital of $40.4 million; and a Term Loan balance of $15.1 million. The Company incurred a loss of $44.8 million for the year ended December 31, 2011. Net cash used in operations for the year ended December 31, 2011 was $35.7 million. In January 2012, the Company sold 2,450,000 shares of common stock under the Cantor Agreement and raised $8.5 million in net proceeds. In February 2012, the Company issued 10,500,000 shares of its common stock in an underwritten public offering. The net proceeds to the Company were $37.7 million, after deducting underwriting fees and estimated offering expenses. The Company has granted the underwriters a 30-day option to purchase up to an aggregate of 1,575,000 additional shares of common stock to cover overallotments, if any. The Company believes that the cash, cash equivalents and marketable securities at December 31, 2011, the $8.5 million raised under the Cantor Agreement in January and the $37.7 million raised in the underwritten public offering in February and interest income on invested funds, will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months. </font></p> <p style="FONT-FAMILY: times"><font size="2">        The Company raised net proceeds of $35.9 million during the year ended December 31, 2011 and $46.2 million during the two months ended February 29, 2012 from the sale of its common stock. During the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs. These capital raising activities may include, but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company continues to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company's negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financing may be dilutive to the Company's stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company's ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms that reduce the Company's economic potential from products under development. If the Company is unable to raise the funds necessary to meet its long-term liquidity needs, it may have to delay or discontinue the development of one or more programs, discontinue or delay on-going or anticipated clinical trials, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or a part of the Company. </font></p></td></tr></table>
CY2010	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1014000	USD
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2802000	USD
CY2009	us-gaap	Repayments Of Subordinated Debt RepaymentsOfSubordinatedDebt	2957000	USD
CY2011	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5000000	USD
CY2010	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10000000	USD
CY2010	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	197000	USD
CY2009	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	176000	USD
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10817000	USD
CY2009	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-2465000	USD
CY2010	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	2000	USD
CY2009	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-12000	USD
CY2010	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-35715000	USD
CY2009	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	12745000	USD
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39501000	shares

Files In Submission

Name	View Source	Status
0001047469-12-002276-index-headers.html	Edgar Link	pending
0001047469-12-002276-index.html	Edgar Link	pending
0001047469-12-002276.txt	Edgar Link	pending
0001047469-12-002276-xbrl.zip	Edgar Link	pending
a2207736z10-k.htm	Edgar Link	pending
a2207736zex-21_0.htm	Edgar Link	pending
a2207736zex-23_1.htm	Edgar Link	pending
a2207736zex-31_1.htm	Edgar Link	pending
a2207736zex-31_2.htm	Edgar Link	pending
a2207736zex-32.htm	Edgar Link	pending
cldx-20111231.xml	Edgar Link	completed
cldx-20111231.xsd	Edgar Link	pending
cldx-20111231_cal.xml	Edgar Link	unprocessable
cldx-20111231_def.xml	Edgar Link	unprocessable
cldx-20111231_lab.xml	Edgar Link	unprocessable
cldx-20111231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g337285.jpg	Edgar Link	pending
g477545.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLDX
Celldex Therapeutics, Inc. Stock $cldx

2012 Q1 Form 10-K Financial Statement

#000104746912002276 Filed on March 08, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLDX Celldex Therapeutics, Inc. Stock $cldx

2012 Q1 Form 10-K Financial Statement

#000104746912002276 Filed on March 08, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLDX
Celldex Therapeutics, Inc. Stock $cldx